Uncategorized Archives - Page 13 of 134

MondayApr 22, 2024 10:30 am

Clene Inc. (NASDAQ: CLNN) Continues Development of Lead Drug Candidate CNM Au8(R) for Neurodegenerative Diseases including Parkinson’s Disease

CNM-Au8 is an oral suspension with demonstrated activity in restoring neuronal health and function by increasing energy production and utilization Treatment with CNM-Au8 investigated in clinical trials adjunctive to standard-of-care exhibits no known drug interactions, and aims to enhance function and survival Nearly 90,000 people are diagnosed with Parkinson's disease every year with no approved drug to slow or halt disease progression currently available The Parkinson's disease treatment market was valued at $4.61 billion in 2022 and is expected to reach $11.98 billion by 2030 In recognition of April as Parkinson’s Disease Awareness Month, IBN is highlighting Clene (NASDAQ: CLNN),…

TuesdayApr 16, 2024 9:45 am

Astiva Health Inc. Committed to Creating Healthcare Model Focused on Collaboration Between Physician and Patient

Duke reports that physician-patient relationships can have profound positive and negative implications on clinical care” The dynamic between a physician and patient can be impacted by the ability to speak articulately, including the knowledge of a foreign language, and racial and cultural differences Astiva Health specializes in innovative health plans tailored to meet the unique requirements of its members Astiva Health has a network of providers that closely matches patients’ demographic background, interest, language and culture. This does not come by luck. Astiva has always been working on improving its provider network and physician-patient assignment, ensuring health plans align with client…

WednesdayApr 10, 2024 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients AVERSA technology can be incorporated into any transdermal patch The company has a broad intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico and Australia Nutriband announced in March 2024 that it will submit a New Drug Application to the FDA seeking approval to market AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch In April 2024, the company announced it had received a contract manufacturing order from…

TuesdayApr 09, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug

Clinical trials of Clene’s lead candidate CNM-Au8(R) have shown notable success in crossing the blood-brain barrier and enhancing the brain's bioenergetic metabolites, essentially "reversing the clock" on what would be considered healthy aging CNM-Au8 has shown promise in clinical trials for both ALS and MS, including improvements in survival rates and clinical function Clene was recently featured in an interview of CEO Rob Etherington on ‘First in Human’ podcast In a significant advancement for the treatment of neurodegenerative diseases, Clene (NASDAQ: CLNN) has innovated CNM-Au8, an oral nanotherapeutic designed to revitalize the brain's mitochondrial function. The potential of this drug…

FridayApr 05, 2024 10:30 am

Astiva Health Inc. — Bridging Healthcare Gaps with Proactive, Culturally Responsive Solutions

A Brookings Institution report indicates significant racial disparities in access to health coverage and in health outcomes Astiva Health is focused on reshaping the landscape of personalized and comprehensive healthcare The company carefully considers needs of its members, creates plans that feature cultural strategies for diverse ethnic groups In a world where racial disparities still run rampant in many ways, including health coverage and outcomes, Astiva Health is focused on meeting the healthcare needs of underserved populations. The company recognizes the diverse challenges within key communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions. “In the…

TuesdayApr 02, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Publication of “Protein Corona Composition of Gold Nanocatalysts” in ACS Pharmacology & Translational Science

The publication provides a comprehensive analysis of proteins from human blood plasma that interact with CNM-Au8(R) CNM-Au8 nanocrystals coated with a protein corona are less prone to clumping compared to those without any coating Certain apolipoproteins found on the nanocrystals' surface, which aid in crossing the blood-brain barrier (“BBB”), were identified, suggesting an enhanced delivery mechanism into the brain The findings enrich the understanding of CNM-Au8's mechanism as preparations for a Phase 3 trial for ALS are underway, scheduled for the second half of 2024 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company…

MondayApr 01, 2024 9:00 am

Sigyn Therapeutics Inc. (SIGY) CEO Discusses Company’s Blood Purification Therapies to Address Cancer and Other Life-Threatening Conditions at the Emerging Growth Conference

Sigyn Therapeutics CEO Jim Joyce reviewed the company’s pipeline of technologies, including ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) to improve patient responses to various cancer therapies, and Sigyn Therapy(TM) to address drug resistant viral and bacterial infections, endotoxemia, and sepsis, a leading cause of hospital deaths in the United States The company created Sigyn Therapy(TM) to treat pathogen-associated disorders that are not addressed with drug therapies Sigyn Therapeutics is developing ChemoPrep(TM) and ImmunePrep(TM), to improve patient responses to chemotherapy and immunotherapeutic antibodies, respectively To reduce toxicity, the company designed ChemoPure(TM) to sweep off-target chemotherapy from the bloodstream before it is able to cause the…

ThursdayMar 28, 2024 9:45 am

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

Longeveron recently released its full-year results for the period ended December 31, 2023, and provided a corporate update The update outlined the company’s plans to prioritize the development of Lomecel-B(TM) in Hypoplastic Left Heart Syndrome (“HLHS”), a rare, pediatric congenital heart condition characterized by an underdeveloped left side of the heart Longeveron plans to complete the enrollment in the ELPIS II trial for HLHS in 2024 The company also reported that it is exploring opportunities to advance its Alzheimer’s disease program through potential partnerships or other sources of funding Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for…

ThursdayMar 28, 2024 9:00 am

Astrotech Corp. (NASDAQ: ASTC) and AgLAB Inc. Use Mass Spectrometer Technology to Significantly Enhance Hemp and Cannabis Production Yield and Profit

The cannabinoid market value in 2023 was $22.23 billion and is expected to grow at a CAGR of 15.3%, resulting in an estimated market value of $60.36 billion The global mass spectrometry market will reach $6.77 billion in 2024 and is expected to grow at a CAGR of 6.25%, reaching $9.17 billion by 2029. Astrotech and subsidiary AgLAB Inc. are using mass spectrometry to boost the profitable yield of hemp and cannabis production The United States has seen a rising awareness of the health and therapeutic benefits of cannabinoids, prompting an expected market increase of 15.3%, from $22.23 billion in…

TuesdayMar 26, 2024 9:45 am

Astiva Health’s Innovative Strategies for Enhancing Senior Mobility and Independence

Astiva Health Inc. is pioneering transformative healthcare for seniors, with a focus on enhancing mobility and promoting independence. This innovative approach places a strong emphasis on seniors as active participants in their healthcare journey, representing a shift towards a more interactive and preventive model of care. Embracing Active Participation Central to Astiva Health's mission is empowering seniors to engage actively in their healthcare decisions, supporting their flourishing in later years. The CDC highlights physical activity's crucial role in preventing chronic diseases among seniors, noting that regular physical activity can significantly reduce health risks associated with inactivity (CDC, 2020). Tailored Exercise…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Clene Inc. (NASDAQ: CLNN) Continues Development of Lead Drug Candidate CNM Au8(R) for Neurodegenerative Diseases including Parkinson’s Disease

Astiva Health Inc. Committed to Creating Healthcare Model Focused on Collaboration Between Physician and Patient

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug

Astiva Health Inc. — Bridging Healthcare Gaps with Proactive, Culturally Responsive Solutions

Clene Inc. (NASDAQ: CLNN) Announces Publication of “Protein Corona Composition of Gold Nanocatalysts” in ACS Pharmacology & Translational Science

Sigyn Therapeutics Inc. (SIGY) CEO Discusses Company’s Blood Purification Therapies to Address Cancer and Other Life-Threatening Conditions at the Emerging Growth Conference

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

Astrotech Corp. (NASDAQ: ASTC) and AgLAB Inc. Use Mass Spectrometer Technology to Significantly Enhance Hemp and Cannabis Production Yield and Profit

Astiva Health’s Innovative Strategies for Enhancing Senior Mobility and Independence

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search